Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansa Biopharma AB ( (SE:HNSA) ) has issued an announcement.
Hansa Biopharma AB announced its intention to raise approximately USD 60 million through a directed share issue aimed at Swedish and international institutional investors. The funds will support the company’s strategic initiatives, including the potential filing of a Biologic License Application with the FDA and preparations for the commercial launch of imlifidase in the U.S. The decision for a directed share issue, as opposed to a rights issue, was made to ensure timely capital acquisition and to attract strategic biotechnology investors, reflecting the company’s proactive approach to strengthening its market position.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a biopharmaceutical company based in Lund, Sweden, specializing in the development of novel immunomodulatory treatments. The company focuses on addressing rare diseases and conditions such as kidney transplants and autoimmune diseases, with a significant market focus on the United States.
Average Trading Volume: 524,776
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.3B
See more insights into HNSA stock on TipRanks’ Stock Analysis page.